On July 30, 2026, the China National Intellectual Property Administration (CNIPA) released the revised Measures for Administration of Priority Examination of Patents (Order No. 85), effective September 1, 2026. It replaces the 2017 Order No. 76 with a new six-chapter, 24-article structure covering general provisions, applicable conditions, filing requirements, review procedures, supervision, and supplementary rules.

Bottom line for foreign applicants: priority examination is no longer a general acceleration tool. Order 85 tightens who can apply, adds real quality-control penalties, and — through a recommendation-letter requirement in Article 11 — appears to exclude foreign entities from the system in practice, not just make it harder to access.

During the 14th Five-Year Plan period (2021–2025), CNIPA processed over 720,000 priority examinations. Order 85 is the agency's response to that volume: fewer applications, processed faster, for cases CNIPA considers strategically important.

What Changed

Scope: Wider for Disputes, Tighter for Applications

Invalidation priority now covers three additional dispute types: administrative rulings under the drug patent dispute early resolution mechanism, patent open licensing dispute mediations, and patent licensing contract arbitration disputes (Article 6).

For patent applications and reexamination requests, Article 5 sets a new bar: the applicant must show "significant innovative value" and "promising prospects for commercialization." Qualifying grounds include involvement in emerging or future industries, key core technology, industries encouraged by provincial or municipal governments, evidence of industrialization or preparation for it, or a Chinese-first filing later pursued abroad.

Article 8 excludes four categories from priority treatment: divisional applications whose parent already received expedited examination; same-day dual filings of an invention and a utility model for the same invention; applications that already received priority or other expedited treatment in the same procedure; and — for applications relying on the "filed abroad after China" ground — cases where evidence shows no real prospect of grant.

Quality Control With Teeth

Article 7 requires patent agencies handling priority requests to maintain good standing and professional competence. Article 13 requires provincial IP offices to justify recommendations in writing and reject anything that looks fraudulent or made in bad faith. Article 22 backs this up with a one-year bar on priority examination requests for applicants or agencies found to have violated the good-faith principle.

Article 19 ties each province's priority-examination quota to the quality of its recommendation work — provinces that wave through weak applications lose allocation; provinces that hold the line gain it.

Procedure

Prior art and design-reference materials are now optional (Article 11), reversing the mandatory submission under the old rules. Article 12 confirms, formally, that priority examination carries no extra government fees. Article 10 requires electronic filing. Article 15 sets fixed timelines: invention applications get a first office action within 45 days and a decision within one year; utility models and designs conclude within two months; reexaminations within seven months; invalidation cases within five months (four for designs).

Foreign Applicants Are Effectively Shut Out

This is the part that matters most for non-Chinese companies. Article 11 requires every priority examination request — for applications, reexaminations, and invalidations alike — to carry a recommendation from a provincial IP office or a relevant State Council department. Aaron Wininger of Schwegman Lundberg & Woessner, whose firm published the first English translation of the order, titled his analysis "CNIPA Releases Revised Measures for Administration of Priority Examination of Patents Excluding Foreigners" and concluded that foreign entities do not appear eligible to use the system at all.

Three workarounds are in circulation, and none of them are reliable:

Filing through a Chinese subsidiary. Anecdotal reports indicate these requests are commonly denied.

Having a Chinese entity file first, then assigning the application to a foreign entity. This runs into China's patent export-control review, which can block or delay the assignment.

Requesting a recommendation directly from the Beijing IP Office. Practitioners tracking this route report no confirmed successful cases so far.

In short: there is currently no dependable path for a foreign applicant with no meaningful China operations to access priority examination under Order 85. Companies with a genuine China footprint — a WFOE or joint venture with real R&D activity, documented commercialization plans, manufacturing partnerships — have a better chance of building a case for provincial recommendation, but even that is unproven under the new rules.

What to Do Before September 1, 2026

Audit pending requests. Anything currently in the priority pipeline under Order 76 should be checked against Article 5's "significant innovative value and commercialization prospects" standard. 

Map your actual China presence. If you operate through a WFOE or joint venture, identify which provincial IP office has jurisdiction and start that relationship now. If you work only through outside patent agencies, ask directly about their track record getting provincial recommendations — it varies widely.

Build commercialization documentation regardless. Manufacturing plans, licensing agreements, market-entry timelines, and partnership MOUs strengthen any recommendation case. Generic statements of commercial value will not meet the new bar.

Look at IP protection centers as an alternative. China's national IP protection centers and rapid rights protection centers run a separate fast-track examination process from priority examination, and for foreign companies without a strong provincial relationship, that channel may be more realistic to pursue than Order 85's priority lane.

Who Gains, Who Loses

Domestic companies in emerging and future industries get a cleaner, less congested fast track, since the new exclusions and quality controls filter out volume filers. Patent agencies with strong provincial relationships and clean compliance records become more valuable. Companies already commercializing in China with real local R&D face a more demanding but navigable process.

Foreign entities without a substantive China presence lose access to priority examination in practice. Volume filers who treated priority examination as a default strategy lose that option entirely. The 45-day first-office-action deadline also compresses the coordination window for cross-border prosecution teams working with Chinese counsel.

Order 85 implements the differentiated, industry-targeted approach called for in China's "IP Powerhouse Construction Outline (2021–2035)": fewer applications, processed faster, with priority reserved for what CNIPA judges strategically important — and, for now, reserved for applicants with a real footprint in China.